Clinician View

Sources & Demo Notes

Transparency, scope, and roadmap for the NAR proof-of-concept.

Investor / Lender Demo Notes

  • This demo is designed for B-Force Demo Day.
  • It is intended to explain the concept, not serve as a working clinical product.
  • All participant names, health values, alerts, and reports are simulated.
  • No real Apple Watch, Apple Health, wearable, or medical device is connected.
  • No real patient data is collected.
  • No diagnosis, treatment, emergency response, or clinical decision should be made from this demo.
  • Proprietary scoring modules are intentionally hidden.

Future Development Roadmap

Phase 1
01
Target: July 2026

Demo Prototype

  • Simulated participant data
  • Demo Day presentation
  • Stakeholder feedback collection
Phase 2
02
Target: August–September 2026

MVP Planning + Technical Scope

  • Developer requirements
  • Data model planning
  • Participant self-check-in workflow
  • Clinician dashboard requirements
  • Compliance / security discovery
Phase 3
03
Target: October–December 2026

MVP Build

  • Manual participant input
  • Clinician dashboard
  • Alert workflow
  • Basic reporting
  • Secure architecture planning
Phase 4
04
Target: Q1 2027

Wearable Integration Research

  • Apple Health / Apple Watch feasibility
  • Wearable API review
  • Data permissions
  • Device limitations
  • Sync reliability testing
Phase 5
05
Target: Q2 2027

Pilot Planning + Validation Preparation

  • Clinic / hospital partner conversations
  • IRB / compliance planning
  • Controlled test group design
  • Clinical validation plan
  • Pilot readiness review

Timeline is dependent on funding, technical partner availability, compliance review, and pilot partner readiness.

Funding Ask: $350,000 to move NAR from simulated proof-of-concept to MVP and pilot-readiness.

Evidence & Citation References

Substance use relapse and recovery research
Sources: NIDA, 2020; SAMHSA, 2025.
Tap for APA references ↓

National Institute on Drug Abuse. (2020, July 6). Treatment and recovery. National Institutes of Health. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery

Substance Abuse and Mental Health Services Administration. (2025). Results from the 2024 National Survey on Drug Use and Health: Detailed tables. U.S. Department of Health and Human Services. https://www.samhsa.gov/data/sites/default/files/reports/rpt56287/2024-nsduh-annual-national-report.pdf

These sources support relapse/recovery context, substance use prevalence, and the need for ongoing recovery support.

Wearable health monitoring research
Sources: Carreiro et al., 2020; Alinia et al., 2021.
Tap for APA references ↓

Carreiro, S., Chintha, K. K., Shrestha, S., Chapman, B., Smelson, D., Indic, P., & Boyer, E. W. (2020). Wearable sensor-based detection of stress and craving in patients during treatment for substance use disorder: A mixed methods pilot study. Drug and Alcohol Dependence, 209, 107929. https://pmc.ncbi.nlm.nih.gov/articles/PMC7197459/

Alinia, P., Cain, C., Fallahzadeh, R., Shahrokni, A., Cook, D., Ghasemzadeh, H., & Shahriari, Y. (2021). Associations between physiological signals captured using wearable sensors and self-reported outcomes among adults in substance use disorder recovery. JMIR Formative Research, 5(7), e27892. https://pmc.ncbi.nlm.nih.gov/articles/PMC8339978/

These sources support the feasibility of wearable sensing in substance use recovery contexts, especially around stress, craving, and physiological signals.

Recovery capital research
Sources: Headid et al., 2024.
Tap for APA references ↓

Headid, R. J., Jacobs, B. A., & Hochstetler, A. (2024). Identifying components of recovery capital that support recovery from substance use disorder. https://pmc.ncbi.nlm.nih.gov/articles/PMC10940757/

This source supports recovery capital as a meaningful concept tied to resources, support systems, and conditions that help people initiate and sustain recovery.

Behavioral health intervention models
Sources: SAMHSA, 2023; NIDA, 2020.
Tap for APA references ↓

Substance Abuse and Mental Health Services Administration. (2023). Digital therapeutics for management and treatment in behavioral health. U.S. Department of Health and Human Services. https://library.samhsa.gov/sites/default/files/pep23-06-00-001.pdf

National Institute on Drug Abuse. (2020, July 6). Treatment and recovery. National Institutes of Health. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery

These sources support digital therapeutics as a behavioral health category and the need for ongoing treatment and recovery support.

Digital health privacy and compliance considerations
Sources: HHS, 2024; FDA, 2022; FDA, 2026.
Tap for APA references ↓

U.S. Department of Health and Human Services. (2024, August 21). Covered entities and business associates. https://www.hhs.gov/hipaa/for-professionals/covered-entities/index.html

U.S. Food and Drug Administration. (2022, September 28). Policy for device software functions and mobile medical applications: Guidance for industry and Food and Drug Administration staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications

U.S. Food and Drug Administration. (2026, January 29). Clinical decision support software: Guidance for industry and Food and Drug Administration staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software

These sources support the need for privacy, security, and regulatory review before moving from a simulated demo to real-world clinical use.

Clinical validation and pilot design
Sources: FDA, 2026; SAMHSA, 2023; Carreiro et al., 2020.
Tap for APA references ↓

U.S. Food and Drug Administration. (2026, January 29). Clinical decision support software: Guidance for industry and Food and Drug Administration staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software

Substance Abuse and Mental Health Services Administration. (2023). Digital therapeutics for management and treatment in behavioral health. U.S. Department of Health and Human Services. https://library.samhsa.gov/sites/default/files/pep23-06-00-001.pdf

Carreiro, S., Chintha, K. K., Shrestha, S., Chapman, B., Smelson, D., Indic, P., & Boyer, E. W. (2020). Wearable sensor-based detection of stress and craving in patients during treatment for substance use disorder: A mixed methods pilot study. Drug and Alcohol Dependence, 209, 107929. https://pmc.ncbi.nlm.nih.gov/articles/PMC7197459/

These sources support the need for staged pilot testing, evidence generation, and clinical/regulatory review before positioning NAR as a validated clinical tool.

Investor Distribution Note

This demo uses simulated data and is not clinically validated. All projected outcomes, risk thresholds, scoring logic, and model performance claims should be supported with citations, pilot data, or clearly labeled as assumptions before formal investor distribution or clinical use.

Protected Concept Area

Cognitive and behavioral scoring modules, the proprietary blending logic, and model weighting details are intentionally not shown in this demo. Details available during qualified follow-up discussion.

Proof-of-concept demo. Simulated data only. Not for clinical use, diagnosis, treatment, emergency response, or real-time patient monitoring.